MatthewPGoetzMD

Breast Cancer

Professor of Oncology and Professor of Pharmacology; Director, Mayo Breast Cancer Specialized Program of Research Excellence; Co-Leader, Women's Cancer Program, Mayo Clinic Cancer Center; Chair, Mayo Breast Research Group

Join to view full profile

Dr. Goetz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Goetz's full profile

Already have an account?

Office
200 1st St SW
Rochester, MN 55905
Phone+1 507-284-2511

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1999 - 2003
University of MichiganResidency, Internal Medicine, 1996 - 1999
University of MichiganInternship, Internal Medicine, 1996 - 1997
University of North Dakota School of Medicine and Health SciencesClass of 1996

Certifications & Licensure

MN State Medical License 1999 - 2025
MI State Medical License 1998 - 2002
American Board of Internal Medicine Medical Oncology

Clinical Trials

Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary Start of enrollment: 2004 Feb 01
Completed
Phase 2
Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors Start of enrollment: 2003 Nov 01
Completed
Phase 1
Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2004 Mar 01
Completed
Phase 2
Liposomal SN-38 in Treating Patients With Small Cell Lung Cancer
Withdrawn
Phase 2
Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2006 Feb 01
Completed
Phase 2
AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery Start of enrollment: 2006 Jul 01
Completed
Phase 1
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer Start of enrollment: 2007 May 01
Completed
Phase 2
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases Start of enrollment: 2003 Nov 01
Completed
Not Applicable
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline Start of enrollment: 2011 Mar 16
Active, not recruiting
Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer Start of enrollment: 2009 May 01
Terminated
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary Start of enrollment: 2009 Sep 01
Completed
Phase 2
Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer Start of enrollment: 2011 Mar 25
Active, not recruiting
Phase 1
Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2011 May 02
Active, not recruiting
Phase 1
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
Completed
Phase 2
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer Start of enrollment: 2013 Apr 10
Active, not recruiting
Phase 2
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer Start of enrollment: 2013 Jan 01
Terminated
Phase 2
Breast Cancer Genome Guided Therapy Study (BEAUTY) Start of enrollment: 2013 Feb 01
Active, not recruiting
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2019 Aug 28
Enrolling by invitation
Phase 2
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer Start of enrollment: 2020 Jan 10
Recruiting
Phase 2
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer Start of enrollment: 2021 Jan 13
Recruiting
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss Start of enrollment: 2020 Jun 08
Active, not recruiting
Phase 3
Roles: Contact
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Start of enrollment: 2023 Oct 31
Recruiting
Phase 3
Roles: Contact
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis Start of enrollment: 2024 Jul 31
Not yet recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

In-Breast Tumor Progression During Neoadjuvant Chemotherapy: Impact on and Factors Influencing Distant Recurrence-Free Survival.
Kathryn M Eckert, Tanya L Hoskin, Carrie A Olson, Matthew P Goetz, Judy C Boughey
Annals of Surgical Oncology. 2024-12-01
OmicsFootPrint: a framework to integrate and interpret multi-omics data using circular images and deep neural networks.
Xiaojia Tang, Naresh Prodduturi, Kevin J Thompson, Richard Weinshilboum, Ciara C O'Sullivan
Nucleic Acids Research. 2024-11-27
CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108.
Vered Stearns, Anne ONeill, Bryan P Schneider, Todd C Skaar, Minetta C Liu
Breast Cancer Research and Treatment. 2024-10-21

Journal Articles

ERβ-Mediated Induction of Cystatins Results in Suppression of TGFβ Signaling and Inhibition of Triple-Negative Breast Cancer Metastasis
Matthew P Goetz, James N Ingle, Proceedings of the National Academy of Sciences
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Matthew P Goetz, Thomas J Saphner, Joseph A Sparano, Lynne I Wagner, Peter M Ravdin, Daniel F Hayes, Adam M Brufsky, Della F Makower, Sunil S Badve, Robert J Gray, Wil..., The New England Journal of Medicine

Lectures

ER+ Metastatic Breast Cancer: Beyond CDK Inhibitors
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Homing in on Anthracyclines' High-Risk Niche in Early Breast CancerDecember 14th, 2024
Mayo Clinic Experts Advance Chemo-Free, Low-Dose RadiationNovember 3rd, 2024
Prognostic Biomarker Identified in Triple-Negative Breast Cancer: Potential to Reduce Chemotherapy UseOctober 30th, 2024
Join now to see all